Switching Antipsychotic Medications: Not Enough, Too Often, or Just Right?

Dr. Weiden has served as a consultant for or on the advisory board of Biovail, Bristol-Myers Squibb, Delpor, Eli Lilly, Genentech, Lundbeck, Janssen, Merck, Novartis, and Vanda. He has received research funding from Janssen, Novartis, Sunovion, and NIMH. He is on the speakers bureau for Janssen, Merck, Novartis, and Pfizer and has participated in CME activities for the American Psychiatric Association, International Congress on Schizophrenia Research, Letters & Sciences, Medscape, Mayo Clinic, UCLA School of Medicine, and U.S. Psychiatric Congress. Dr. Freedman has reviewed this editorial and found no evidence of influence from these relationships.